JMP keeps MGI at underperform

JMP Securities analyst Charles C. Duncan reiterated MGI Pharma, Inc. at market outperform and a $14 price target. While the company's third-quarter financial results were above JMP's and consensus expectations, could mean management set the bar low, according to the analyst. Sales of Aloxi, Dacogen, and Gliadel outperformed expectations following two disappointing quarters. Shares of the Bloomington, Minn.-based biopharmaceutical company were up $1.21, or 6.66%, at $19.38. (Nasdaq: MOGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.